Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

Cardiologists have performed what they believe to be the world’s first substernal lead extraction, sharing their experience in JACC: Case Reports.[1]The device being extracted, Medtronic’s Aurora EV-ICD, received U.S. Food and Drug Administration (FDA) approval in October 2023.

Cardiologists perform world’s first substernal lead extraction

The 49-year-old patient was not in pain or suffering any complications, but he wished to have his extravascular ICD removed once his symptoms improved. The care team agreed to extract it after a long discussion, and they said it was "easier than expected." 

Interventional cardiology procedure in a cath lab at Beaumont Hospital.

SCAI shares STEMI recommendations for cardiologists and cath labs

“This document represents a collective effort to refine and advance the standards of care in STEMI management," according to one cardiologist behind the project. 

Ron Blankstein, MD, Brigham and Womens Hospital, explains a study using AI opportunistic screening in non-cardiac CT scans looking for coronary artery disease.

Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

The OmniaSecure defibrillation lead, which Medtronic describes as “the world's smallest transvenous defibrillation lead,” has a size of just 4.7 French.

Medtronic’s OmniaSecure, the smallest ICD lead of its kind, linked to long-term durability

Reliability modeling suggests the small-diameter defibrillation lead, already linked to positive early outcomes, should last patients for at least 10 years—and likely longer. 

Video of Jamshid Maddahi, MD, UCLA, explaining why flurpiridaz will change cardiac imaging and increase the adoption of PET cardiac imaging.

A closer look at how FDA's flurpiridaz approval will impact nuclear cardiology

The newly approved PET radiotracer is expected to improve patient care significantly. “We have been able to reach the pinnacle of myocardial perfusion imaging with flurpiridaz," one expert said.

artificial intelligence in cardiology

FDA grants AI-powered ECG screening tool for aortic stenosis its breakthrough device designation

The FDA clearly sees significant potential in this new screening software from New York-based AccurKardia.

Banner ASC in Sun City, Arizona.

Low doses of radiation still increase risk of leukemia, lymphoma and myeloma

A new study found cumulative radiation exposure of 16 mSv to red bone marrow can cause an increased rate of some hematological malignancies.

AURORA trial results for Flurpiridaz F-18 PET vs. SPECT discussed by principal investigator Jamshid Maddahi, MD.

'This could be a paradigm shift': How PET with newly approved flurpiridaz compares to SPECT

GE HealthCare's flurpiridaz, the PET radiotracer that recently received FDA approval, offers several key benefits over SPECT. Jamshid Maddahi, MD, discussed the details in an exclusive interview. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Trimed Popup
Trimed Popup